T cell and natural killer cell

"T cells and natural killer (NK) cells" is not a single molecular target but rather refers to two distinct types of immune effector cells. Both play critical roles in the body's defense against infections and cancer but belong to different arms of the immune system. **T cells**, particularly cytotoxic (CD8+) T cells, are part of the adaptive immune system. They recognize specific antigens presented by major histocompatibility complex class I molecules on infected or malignant host cells. Upon activation—requiring antigen recognition via their unique T-cell receptor plus costimulatory signals—they proliferate, secrete cytokines, and directly kill target cells through release of perforin/granzymes or engagement of death receptors[3]. **Natural killer (NK) cells** are large granular lymphocytes that function as part of the innate immune system. Unlike T-cells, they do not require prior sensitization to antigens; instead, they use a balance between activating and inhibitory receptors to detect "altered self," such as virally infected or transformed tumor cells that have downregulated MHC class I expression[2][4][5]. When activated by loss of inhibitory signals or presence of stress ligands on targets, NK cells induce apoptosis via perforin/granzyme release or death receptor pathways[2][4][5]. They also secrete cytokines like IFN-gamma that modulate other components of immunity[1][8]. Both **cytotoxic T-cells ("killer" T-cells)** and **natural killer (NK) cells** can destroy virus-infected or cancerous host targets but differ fundamentally in their mechanisms for recognizing these targets—antigen-specific versus pattern-based recognition—and in their place within adaptive versus innate immunity[3][4]. Because "T Cells and Natural Killer Cells" is not a single molecule/receptor/target but rather two broad classes/cell types with many subtypes each—and because drugs typically target specific molecules expressed by these populations rather than the entire population itself—this entry should be considered **incorrect as a therapeutic target name**, per your conventions. > *If you seek structured information about druggable molecular targets related to these populations—for example "CD3", "CD8", "PD1", "NKG2D", etc.—please specify which molecule/receptor/subtype you mean.* --- *Note*: No direct lists exist for interacting drugs/mechanisms/biomarkers/safety concerns because this entry does not refer to a discrete molecular entity. Drugs may act on surface proteins expressed by either population (e.g., anti-CD3 antibodies targeting all mature T-cells; checkpoint inhibitors targeting PD1/PDL1 axis affecting both), but there is no drug that specifically binds “T Cell AND Natural Killer Cell” as one unified entity. If you need information about individual markers/molecules commonly targeted on either population—such as CD3/TCR complex on T-cells or NKG2D/CD16/CD56 on NK-cells—please clarify your request so structured data can be provided at the appropriate level.

Other names

T lymphocyte and NK cellcytotoxic T cell and NK cellCD8+ T cell and NK cellkiller lymphocytes